DaVita Inc. $DVA Position Lessened by Yousif Capital Management LLC

Yousif Capital Management LLC trimmed its position in shares of DaVita Inc. (NYSE:DVA) by 5.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,520 shares of the company’s stock after selling 524 shares during the period. Yousif Capital Management LLC’s holdings in DaVita were worth $1,356,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of DVA. Doma Perpetual Capital Management LLC raised its holdings in shares of DaVita by 172.3% during the first quarter. Doma Perpetual Capital Management LLC now owns 288,360 shares of the company’s stock worth $44,110,000 after acquiring an additional 182,476 shares in the last quarter. Northern Trust Corp increased its position in DaVita by 20.2% during the first quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock worth $136,240,000 after buying an additional 149,858 shares during the last quarter. Nuveen LLC acquired a new position in DaVita during the first quarter worth $20,218,000. Rovin Capital UT ADV acquired a new position in DaVita during the first quarter worth $18,442,000. Finally, Amundi increased its position in DaVita by 16.0% during the first quarter. Amundi now owns 517,690 shares of the company’s stock worth $79,584,000 after buying an additional 71,304 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Stock Performance

NYSE DVA opened at $128.10 on Tuesday. The firm has a 50-day simple moving average of $132.46 and a 200 day simple moving average of $138.05. DaVita Inc. has a twelve month low of $122.93 and a twelve month high of $179.60. The stock has a market cap of $9.16 billion, a PE ratio of 12.60, a PEG ratio of 0.90 and a beta of 1.13.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, beating the consensus estimate of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business had revenue of $3.38 billion during the quarter, compared to analysts’ expectations of $3.36 billion. During the same quarter last year, the company earned $2.00 earnings per share. The firm’s revenue was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Insider Buying and Selling at DaVita

In related news, insider James O. Hearty sold 2,351 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the completion of the sale, the insider owned 26,038 shares in the company, valued at approximately $3,905,700. This trade represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Wall Street Zen downgraded shares of DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Barclays lowered their target price on shares of DaVita from $160.00 to $149.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 9th. Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a research report on Wednesday, October 8th. Truist Financial set a $140.00 target price on shares of DaVita in a research report on Tuesday, October 14th. Finally, Bank of America lowered their price target on DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a research report on Wednesday, September 10th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, DaVita has an average rating of “Reduce” and an average price target of $153.25.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.